Combining paclitaxel with repurposing drugs improve ovarian cancer management

Autores

  • Mariana Nunes Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal.
  • Catarina Brandão Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal.
  • Sara Ricardo Differentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto/Institute of Molecular Pathology and Immunology of the University of Porto (Ipatimup), 4200-135 Porto, Portugal. Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal. TOXRUN – Toxicology Research Unit, University Institute of Health Sciences, CESPU, CRL, 4585-116 Gandra, Portugal.

DOI:

https://doi.org/10.51126/revsalus.v4iSup.301

Palavras-chave:

chemoresistance, combination therapy, drug repurposing, ovarian cancer, paclitaxel

Downloads

Os dados de download ainda não estão disponíveis.

Downloads

Publicado

2022-04-06

Edição

Vol. 4 N.º Sup (2022): Suplemento da RevSALUS - Revista Científica Internacional da RACS

Secção

Pósteres

Licença

Creative Commons License

Este trabalho encontra-se publicado com a Licença Internacional Creative Commons Atribuição-NãoComercial-SemDerivações 4.0.

Como Citar

Combining paclitaxel with repurposing drugs improve ovarian cancer management. (2022). RevSALUS - Revista Científica Internacional Da Rede Académica Das Ciências Da Saúde Da Lusofonia, 4(Sup), 79. https://doi.org/10.51126/revsalus.v4iSup.301

Artigos mais lidos do(s) mesmo(s) autor(es)